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Skeletal muscle dysfunction (SMD) often occurs in patients with COPD, affecting their quality
of life and mitochondrion is one of the cellular organelles involved in the pathogenesis of SMD
in COPD.
The aim of this study was to investigate exercise capacity and mitochondria skeletal muscle
oxidative processes using a pilot study, with 20 COPD patients and 10 healthy subjects, prior to
and following LABA treatment.
The two groups were similar for BODE (2e7) and GOLD stages (2e3), and no one was
cachectic or more symptomatic. The patients were randomized according to a distribution list.
The Cycle Ergometry test with tau evaluation was used to determine exercise capacity,
while a skeletal muscle biopsy for cytochrome oxidase (CytOX) activity evaluation was used
to determine mitochondria skeletal muscle oxidative processes.
In six of the COPD treated patients the individual values of tau and CytOX activity showed
inversely parallel changes with a significant relationship between the tau values and the CytOX
activity. No significant differences in tau values were observed in healthy subjects.
In conclusion, LABA treatment may improve skeletal muscle oxidative processes, enhancing
the CytOX activity and, at least in some COPD patients, such effects could be strictly linked to
the kinetic exchanges occurring at skeletal muscle level, implying an important link betweenof Experimental Medicine, sect. of Pharmacology ‘‘L. Donatelli’’, Faculty of Medicine and Surgery,
ntinopoli 16, 80138. Tel.: þ39 (0)815667651; fax: þ39 (0)815667503.
nina2.it (B. D’Agostino).
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84 B. D’Agostino et al.the regulation of oxygen uptake, energy production and the exercise capacity of these
patients.
Nevertheless, further studies are required and a better understanding of the mechanism(s)
underlying LABA effects might allow us to identify or unmask new therapeutic target(s) in such
patients.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a pulmo-
nary disorder, characterised by reduced maximum expira-
tory flow and slow, forced emptying of the lungs, due to
varying combinations of diseases of the airways and
emphysema. This definition focuses exclusively on the
lungs, but various recent studies have provided evidence
that COPD is often associated with significant extrapulmo-
nary abnormalities, the so-called ‘‘systemic effects of
COPD’’, including cardiovascular disease1 diabetes,2 oste-
oporosis,3 and skeletal muscle dysfunction (SMD).4 The
impact of these systemic effects is clinically relevant and
their analysis could contribute to a better understanding
and management of the disease. Exercise limitation, an
important feature of COPD that results in a reduced quality
of life, has been traditionally explained by the increased
effort of breathing and dynamic hyperinflation,5 although
several recent studies have clearly shown that SMD is often
a very significant contributor to exercise limitation.6 The
precise cellular and molecular mechanisms leading to
skeletal muscle dysfunction in the COPD patients are
unclear.7,8 However, sedentarism, low-grade chronic
systemic inflammation, and tissue hypoxia, among other
factors, can contribute to SMD in these patients. These
mechanisms are believed to cause mitochondrial dysfunc-
tion,9,10 enhanced skeletal muscle apoptosis11,12 and
exercise-induced muscle fiber death.13,14
Recently, Wende et al., documented an increase of
cytochrome oxidase subunits (CytOX) II and IV in the skel-
etal muscle of b-agonist-injected mice,15 while other
studies indicate the formoterol as an efficient agent able to
prevent muscle weight loss in tumor-bearing rats16 and to
induce protein accretion.17
The b2-sympathomimetic agonists together with anti-
cholinergics, are the bronchodilators currently available for
use in COPD. There are few studies available on the effects
of b2-agonists on the exercise capacity of COPD
patients.18,19 Therefore the aim of this study was to
investigate exercise capacity using the cycle ergometry test
and skeletal muscle oxidative metabolism, evaluating
cytochrome oxidase activity prior to and following LABA
treatment in both healthy and COPD subjects.
Methods
Study subject
In this pilot study, 20 outpatients with the diagnosis of
stable COPD and 10 healthy subjects were evaluated. The
subjects were recruited from the outpatient clinics of the
Respiratory Pathophysiology Department of Cava de’Tirreni Hospital, with a diagnosis of COPD, made as defined
by the American Thoracic Society (ATS) and European
Respiratory Society (ERS)20 and a history of smoking >10
packets-yrs, in a stable condition of disease for at least 1
month, and matching our inclusion criteria. A complete
medical history was obtained for each patient, which
included a standard American Thoracic Society (ATS)
symptom questionnaire (ATS-DLD 34), past medical history
and evaluation of atopy. Standard posteroanterior (PA) and
lateral chest roentgenograms were obtained for each
patient and read to exclude any other disease. Baseline
characteristics are shown in Table 1. The two groups were
similar for BODE and GOLD stages, and no one was
cachectic or more symptomatic. The patients were
randomized according to a distribution list. Exclusion
criteria were as follows: patients had evidence of pulmo-
nary hypertension detected by eco-Doppler evaluation;
chronic respiratory failure (PaCO2> 45 mmHg or 6 kpa at
rest); other respiratory diseases, cardiac disease, regular
use of prednisone/day, or recent respiratory tract infec-
tion; a need for therapy other than the study or reference
drug and finally any patients who required more than
4 puffs per day of short-acting-b2-agonist during the run-in.
On the basis of the specific limitations of the Committee of
Medical Ethics, the control group was derived from subjects
attending our Pulmonary Function Laboratory for preoper-
ative evaluation: the patients were awaiting minor and
elective surgery (such as orthopaedic disorders, inguinal
hernia, eye and ear surgery, haemorrhoids) for which
pulmonary tests are routinely performed. All patients
signed their informed consent after being made fully aware
of the goals, methods and risks of the study. The Institu-
tional Committee for Ethics in Human Research of our
hospital approved the muscle biopsy applied in the study
(No. 177 of 18 April 2007). All the aspects of this study
comply with the declaration of Helsinki.
Study design
This was a single-blind, placebo-controlled, randomized
study: eligible patients were randomized to receive, before
the constant CPET at day 8, inhaled formoterol (12 mg) via
a single-dose, breath-activated inhaler (Aerolizer dry
powder capsules for inhalation; Novartis; Basel,
Switzerland), or placebo matching formoterol. Formoterol
and placebo were administered in a single-blind manner:
the patients were unaware of the drug delivered. The
primary analysis was clinical evaluation of arterial blood
gases measurements, pulmonary function (including body
pletismography) and DLCO. On day 1, the BODE index for
a systemic evaluation of COPD patients in all observed
subjects was obtained using a 6-min walking test.21 On day
Table 1 Demographic and spirometric characteristics of the COPD and healthy subjects.
COPD LABA (NZ 10) COPD control (NZ 10) Healthy (NZ 10)
Age 63.8 3.43 (48e79) 63.63 1.532 (57e72) 64.02 0.924 (59e68)
BMI 40.7 (26.9e52.6) 40.4 (31.8e47.9) 41 (30.5e47)
Weight 69.3 4.652 (42e92) 68.67 3.215 (51e84) 69.63 2.895 (49e81)
Height 169.40 2.088 (156e176) 169.33 1.554 (161e176) 169.43 1.554 (159e176)
BODE 4.6 0.77 (2e8) 4.5 0.522 (2e7) e
GOLD 2.6 0.163 (2e3) 2.70 0.153 (2e3) e
FEV1 % pred 46.08 4.152 (30.2e64.8) 45.70 3.612 (33e68) 95.5 1.462 (89e103)
FEV1/VC 50.55 2.639 (36.5e63.8) 50.23 2.132 (38.9e59.7) 77.9 0.862 (74e83)
ITGV % pred 143.7 7.449 (120e181) 144.7 5.950 (128e184) 99.7 1.995 (89e109)
RV % pred 175.90 16.579 (130e270) 164.60 8.956 (135e189) 99.7 3.190 (87e119)
DLCO % pred 41.50 1.327 (35e48) 43.30 2.129 (35e50) 95.5 2.078 (87e102)
The range of data is reported in parenthesis.
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subjects’ repeated assessment of pulmonary function
(including body pletismography) and the bronchodilator
response to formoterol (12 mg) was evaluated. On day 4,
each subject underwent a Cardio-Pulmonary-Exercise-Test
(CPET) with ramp protocol in order to obtain the anaerobic
threshold. On day 6, a 6-min CPET constant work rate
protocol with a workload at 50% of anaerobic threshold was
applied to calculate the tau (VO2 kinetics analysis of the
‘‘phase 2’’ of the response, which should more closely
reflect gas exchange kinetics occurring at the skeletal
muscle level). At the end of test, a muscle biopsy was
performed on COPD patients. On day 8, we repeated the
6-min CPET in all subjects evaluated in the study. However,
all COPD patients were randomized to receive formoterol
12 mg or placebo 1 h before the test. At the end of the tests
a muscle biopsy was repeated in all COPD patients. Healthy
subjects did not receive any medication, nor was a muscle
biopsy performed (Fig. 1).
Muscle biopsy
Tru-Cut biopsies were obtained from the right (day 6) and
left (day 8) vastus lateralis using a 14 Ga TW*6 needle. The
skin and muscle were anesthetized with 2% lidocaine, and
samples were taken, immediately snap-frozen in liquid0
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anae
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1 43
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1DLCO: Diffusion capacity for carbon monoxide
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evaluations
Figure 1 Study design procenitrogen and stored at 80 C until cytochrome oxidase
activity determination.
Cytochrome oxidase activity
Samples of skeletal muscle were finely minced, diluted 1:10
w/vol and homogenized in modified ChappelePerry
medium 1 mM ATP, 50 mM Hepes buffer adjusted to pH 7.4,
100 mM KCl, 5 mM MgCl2, 1 mM EDTA, 5 mM EGTA. The
homogenate was then diluted 1:2 (v/v) in the same medium
with lubrol (100 mg/g tissue) in order to unmask tissue
enzyme activity. Samples were left standing in ice for
30 min and thereafter cytochrome oxidase (CytOX) activity
was determined polarographically at 25 C, using Clark
oxygen and a modification of the Aulie & Grav procedure.22
Homogenate proteins (50e100 mg) were added to 1.5 ml of
reaction medium containing 30 mM cytochrome c, 4 mM
rotenone, 1.5 mM dinitrophenol (DNP), 10 mM sodium mal-
onate and 75 mM Hepes buffer, at pH 7.4. The addition of
substrate (4 mM sodium ascorbate with 0.3 nM N,N-N0N0-
tetramethyl-p-phenylene-diamine) to the reaction medium
caused oxygen consumption to commence. In order to take
into account the oxygen consumption due to the auto-
oxidation of ascorbate rather than the CytOX catalyzed
reaction, measurements were also performed in the
absence of homogenate in the reaction medium. CytOX2  
for
robic
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86 B. D’Agostino et al.activity was then measured as the difference between the
rate of oxygen consumption observed in the presence of the
homogenate and the rate observed in its absence.
Statistical analysis
Group data are expressed as mean (SD) or median (range).
Since our data are based on small patient populations with
data that are not normally distributed, we used the Manne
Whitney U-test for comparison between non-parametric
tests. Spearman’s rank correlation coefficient test was used
to examine the association between functional data and
cytochrome oxidase activity. Probability values of p< 0.05
were accepted as significant. Analysis was performed using
the statistical package SPSS 17.0.
Additional information regarding methods is published
online in Supplementary data.
Results
Basal values
The arterial gas analysis of COPD patients revealed a mean
value of PaO2 of 10.00 0.8 kpa and a mean value of PaCO2
of 5.56 0.2 kpa. The demographic and spirometric char-
acteristics, together with the GOLD and BODE stages of
study subjects are shown in Table 1.
Bronchodilation response and anaerobic threshold
The bronchodilator response after inhalation of LABA did
not show any significant difference in FEV1 and TGV in COPD
patients according to our selection criteria. In terms of
FEV1 the increase (in % of basal values and in absolute
values) was 5.4 6.9% (80 84 ml); in terms of TGV (in % of
basal values) the LABA elicited a decrease of 0.98 4.54%.
The ramp CPET protocol confirmed a ventilatory limita-
tion by a lowbreathing reserve (with the patient approaching
or reaching his or her ventilatory capacity, measured as MVV
e Maximum voluntary ventilation), low VO2 max and early
anaerobic threshold. The rampCPET protocol was stopped inTable 2 Medians (and range) of anaerobic threshold (calcula
(nmoles O2/minmg/prot) and tau (s) at constant work rate select
COPD patients and healthy subjects.
COPD LABA (NZ 10
AT (% VO2 max) 60 (20e80)
VO2 max6 (ml) 739 (388e1311)
VO2 max8 (ml) 760 (357e1355)
VO2 max% 96.3 (79e117)
CytOX6 (nmoles O2 min
1/mg/prot) 96 (66e180)
CytOX8 (nmoles O2 min
1/mg/prot) 122.3 (85e216)
CytOX% (day 8 vs. day 6) 128.7 (81e328)
Tau6 (s) 54.6 (22.5e75.6)
Tau8 (s) 44.6 (14.9e58)
Tau% (day 8 vs. day 6) 76.7 (43e110)two patients (No. 3 and No. 8) because of dyspnea; all other
patients stopped because of fatigue.
Tau and CytOX activity on day 6
On day 6, after the choice ofworkload, themean value of VO2
reached at the end of the constant work rate exercise was
745.2 322.8 ml/min, with an oxygen pulse of 7.4 3.2 ml/
beat. The mean values of anaerobic threshold and tau values
ofall COPDpatientsandhealthy subjectsareshown inTable2.
Moreover, for COPD patients only, CytOX activitymean values
are also shown in Table 2, and CytOX activity and tau indi-
vidual value are shown in Table 3. The day 6 values were
utilized as a starting value in order to evaluate the effects of
the administration of LABA on constant CPET and CytOX
activity on day 8.
Tau and CytOX activity values on day 8
With the cycle ergometry tests, themedians of tau andCytOX
activity of skeletal muscle mitochondria in COPD LABA-
treated patients were lower and, respectively, higher than
COPD control patients (Table 2), but the statistical analysis
did not reveal significance in reason of the wider range of
values of LABA-treated patients (Table 3). It is worth
mentioning that six COPD LABA-treated patients showed
a decrease in tau greater than the maximum decrease in
COPD control patients (Fig. 2), and that the same six patients
showed an increase in CytOX activity of skeletal muscle
mitochondria greater than the maximum increase in COPD
control patients (Fig. 3). Moreover, the decreases in tau
values observed in COPD treated patientswere strictly linked
to the CytOX activity observed in the same patients (Fig. 4).
Discussion
There is evidence to suggest that the mitochondrion is one
of the cellular organelles involved in the pathogenesis of
SMD in COPD.6
Our results indicate that a LABA, such as formoterol,
induced, at least in some cases, an improvement inted with the ramp protocol), cytochrome oxidase activity
ed as 50% of anaerobic threshold reached in ramp protocol, in
) COPD control (NZ 10) Healthy (NZ 10)
45 (30e80) 85 (70e120)
748 (396e1305) 1090 (915e1478)
828 (380e1367) 1078 (836e1453)
106.4 (87e114) 98 (91e108)
96.5 (48e165) e
89.7 (41e172) e
96.1 (79e117) e
49.5 (19.9e69.4) 51 (23.7e66.8)
53.3 (21.3e67.3) 48.4 (21.5e63)
106.5 (92e109) 93.5 (90e109)
Table 3 Individual values of cytochrome oxidase activity (nmoles O2/min mg/prot) and tau (s) at constant work rate selected
as 50% of anaerobic threshold reached in ramp protocol, in COPD patients and healthy subjects.
COPD LABA COPD control Healthy
CytOX6 CytOX8 CytOX% Tau6 Tau8 Tau% CytOX6 CytOX8 CytOX% Tau6 Tau8 Tau% Tau6 Tau8 Tau%
1 81 103 127 66.4 55.9 84 48 41 85 58.5 63.8 109 61.2 63 103
2 66 216 328 34.9 14.9 43 70 82 117 19.9 21.3 107 24.9 27.1 109
3 101 100 99 22.5 24.8 110 143 128 89 24.2 25.4 105 23.7 21.5 91
4 103 134 130 60.7 44.6 73 100 85 84 48.6 52 107 52.7 48.4 92
5 91 137 150 56.55 27.5 49 126 129 103 34.8 38 109 42.0 38 90
6 180 185 103 52.4 165 172 104 69.4 67.3 97 63.7 59.9 94
7 112 92 82 47.2 51.5 109 95 99 105 50.4 54.5 108 49.4 48.4 98
8 105 85 81 52.7 53 101 68 54 79 52.9 56.1 106 52.9 48 91
9 74 137 185 58.3 39.9 68 88 85 96 44.5 40.9 92 49.1 50.1 102
10 83 111 134 75.6 58 77 98 94 96 62.4 58.7 94 66.8 62.1 93
Skeletal muscle dysfunction in COPD 87exercise capacity in COPD patients during constant load
exercise, enhancing the skeletal muscle oxidative
processes, with no differences found in heart rates,
allowing us to speculate on the involvement of mitochon-
drion in the pathogenesis of SMD in COPD.
The lack of any significant changes in heart parameters
rules out an effect of LABA on heart rate during exercise.
Indeed, in order to unmask the contribution of the non-
pulmonary response, our study was performed applying CLE
according to the ATS/ACCP statement,23 for its clinical
relevance in monitoring responses to therapeutic inter-
vention in patients with stable COPD.24 The CLE allows
evaluation of the cardio-respiratory response to exercise
and provides an integrated approach to the evaluation of
COPD symptoms and their modifications following therapy.
Furthermore, our protocol takes into account the expi-
ratory airflow limitation in COPD that leads to air trapping
(hyperinflation), whose impact on symptoms and impair-
ment at rest and during exertion is increasingly recognized
to be central to COPD.25Tau
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of kinetic, was excluded.Several authors have shown that bronchodilators that
mediate improvements in hyperinflation also allow flow-
limited patients to improve their exercise capacity.10,26 In
our study, any patient who had a bronchodilatory response
in terms of FEV1 and air trapping to formoterol was
excluded. Moreover, there was no relationship between the
improvement of tau values, the scores related to the
obstruction degree (GOLD) and multidimensional index
(BODE) in the COPD treated group, suggesting that the
above index is not a major or completely exhaustive indi-
cator of exercise limitation.
To rule out any training effect in COPD treated
patients, it is important to note that in healthy subjects
and COPD control patients, no differences in tau values
during the 6-min CPET protocol were observed. However
a training effect is observed after weeks or months of
intensive and constant training and the subjects enrolled
in our study repeated the 6-min CPET after just two
days. In line with our findings, Liesker et al., showed
a significant effect of formoterol on exhaustion time0
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Figure 3 Relationship of CytOX between COPD LABA-treated patients (circles) and COPD control patients (triangles). Closed
circles non responder COPD patients. Open circles responder COPD patients. Patient No. 6 of COPD LABA patients, with a slow
component of kinetic, was excluded.
88 B. D’Agostino et al.during an incremental work rate protocol in COPD
patients.19
Moreover, our findings showed that the activity of cyto-
chrome oxidase, which is considered a key oxidative
enzyme,27 was significantly enhanced following bronchodi-
lator administration in the skeletal muscle mitochondria of
COPD patients who improved exercise kinetic. Other authors
have documented an upregulation of CytOX genes expression
in trainedCOPDpatients,28 and in amurinemodelMiuraet al.,
recently showed that mRNA expression of peroxisome pro-
liferator-activated receptor-coactivator PGC-1, which may
promote mitochondrial biogenesis in skeletal muscle, was
increasedbyb2-agonists suchas clenbuterol and its increase in
response toexercisewasdue,at least inpart, to theactivation
ofb2-adrenergic receptor.
29 Thismusculareffect ofb-agonists
concords with their effects on the remodeling of adipose
tissue, where b-agonists induced mitochondrial biogenesis
and increased oxidative capacity.30 In our study, the b-agonistFigure 4 Relationship between drug-induced modifications of
cytochrome oxidase activity and tau. COPD LABA-treated
patients (circles) and COPD control patients (squares). Patient
No. 6 of COPD treated patients, with slow component of the
kinetics,was excluded, (yZ130,4e-0,0037; R2Z0,706; pZ0,004).effect had a rapid onset, being evident 1 h after administra-
tion of the drug. It cannot therefore be attributed to a varia-
tion in the mitochondrial content of tissue or an enhanced
concentration ofmitochondriamolecular components, as also
described by others in COPD patients,31 but rather to an
involvement of their kinetic properties. A question that arose
at this point related to the effects of a single inhalation of
formoterol on peripheral muscle biochemistry and function.
On this subject, several studies have shown that the systemic
absorption of inhaled formoterol is rapid; in fact the plasma
peak caused by substance overflow into the systemic circu-
lation is seen within few minutes.32,33
Our study has certain limitations that deserve comment.
Firstly, mitochondrial oxidase activity was measured in
COPD patients only. For ethical reasons, muscle biopsy in
healthy subjects was not permitted, but the mitochondrial
oxidase activity was unaffected in the COPD control group.
Secondly, we did not directly investigate the potential
mechanisms that explain our observations. However, one
could be linked to the effect of long-acting b-agonists on
TNFa,34 a cytokine that is particularly important in the low-
grade systemic inflammation observed in COPD, which can
influence the activity of mitochondrial oxidase.35
Overall these data suggest that the LABA effects on the
CytOX activity is strictly linked to the tau value in COPD
patients, probably on the basis of an ‘‘all or nothing’’ type
mechanism. This effect should more closely reflect gas
exchange kinetics occurring at the skeletal muscle level,
implying an important link between the regulation of oxygen
uptake, energy production and exercise capacity in these
patients. However, further studies on LABA in COPD patients
are required and a better understanding of the mechanism(s)
underlying their effects could allow us to identify or unmask
new therapeutic target(s) in these patients.Acknowledgments
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